National Medicare Coverage Policies For Genetic Tests Suggested By Insurers
This article was originally published in The Pink Sheet Daily
In response to a CMS call for input on revising its list of potential candidates for national coverage determinations in Medicare, AHIP suggests the agency stop relying on local carriers to determine payment for genetic tests. Biopharmaceutical groups raise concerns that CMS may be signaling a move toward a new standard for Medicare coverage.
You may also be interested in...
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Former CMS acting administrator Andy Slavitt says agency’s direction during Biden administration depends on nominee, but trust fund’s looming insolvency will be ‘an issue you can’t avoid.’ The president’s priorities around health equity, racial justice and mental health will make their way into CMS policy and demonstration models, Slavitt suggests.
Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.